Targeted radionuclide treatment for neuroendocrine tumours improves quality of life

13 Jun 2017


A study presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging reports that a novel peptide receptor radionuclide therapy significantly improves wellbeing for patients with malignant neuroendocrine tumours.

Medical Xpress


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story